<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056237</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-1002</org_study_id>
    <nct_id>NCT01056237</nct_id>
  </id_info>
  <brief_title>Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis</brief_title>
  <official_title>Research Institute of Nephrology, Jinling Hospital,</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhi-Hong Liu, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An multi-site, randomized, prospective study to compare the efficacy and safety of
      multi-target therapy as continuous induction and maintenance treatment versus CTX- Aza
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Azathioprine (AZA) has been used for maintenance therapy of lupus nephritis for many years.
      We compare the efficacy and safety of multi-target therapy as continuous induction and
      maintenance treatment vs CTX-Aza.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy and safety of multi-target therapy as maintenance treatment for lupus nephritis with Aza.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Multi-target therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Tarcrolimus+mycophenolate mofetil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azathioprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aza</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multi-target therapy</intervention_name>
    <description>Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)</description>
    <arm_group_label>Multi-target therapy</arm_group_label>
    <other_name>Tacrolimus+mycophenolate mofetil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>1.0-2.0mg/kg/d</description>
    <arm_group_label>Azathioprine</arm_group_label>
    <other_name>Aza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who signed written informed consent form

          2. SLE patient, aged between 18-65 years, female or male;

          3. Patients diagnosed lupus nephritis according to ISN/RPS 2003 classification criteria,
             class Ⅲ, Ⅳ,Ⅳ+Ⅴ, Ⅲ+Ⅴ or Ⅴ LN by renal biopsy

          4. All patients had received induction therapy for 6 months with multi-therapy (FK506 +
             MMF) or intravenous CTX pulses.

          5. Patients were recruited when received partial remission or complete remission after 6
             months induction therapy.

        Complete remission: proteinuria &lt;0.4 g/24h, negative urine sediment, serum albumin &gt;35 g/L,
        elevated scr &lt;0.3mg/dl, no extra-renal complications; Partial remission: proteinuria &lt;1.0
        g/24h, urine RBC &lt;50X104/ml without casts, serum albumin &gt; 30 g/L, elevated Scr
        &lt;0.3mg/dl,no extra-renal complications.

        Exclusion Criteria:

          1. Patients who didn't sign written informed consent form or could not obey the protocol.

          2. Patients who didn't received the CR or PR criterion.

          3. Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the
             normal upper limit or who have active hepatitis.

          4. WBC &lt;3000/mm3 in peripheral blood .

          5. Patients with central nervous system symptoms. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhihong Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

